At the recent IMPAKT Breast Cancer Conference, 2 – 4th May, Brussels, ecancer´s Peter Goodwin talks to Ana Vivancos about her pioneering research in cancer genomics and work contributing to improved phase I clinical studies and best therapies for patients.
Related Posts
Grant for the research in colorectal cancer
The “Olga Torres” Foundation awards to a VHIO research group a grant for the research on tumor stem cells
07 Sep 2010
ICREA: promoting latest discovery to better elucidate cancer evolution and tumor heterogeneity
Considering cancer from an evolutionary perspective in order to better understand its vast complexity and clonal dynamics is undoubtedly opening…
09 Mar 2017
LIF, a gene involved in the proliferation of tumour stem cells
The Vall d’Hebron Institute of Oncology (VHIO) has published a new study describing a new molecular mechanism that regulates the renewal of the glioma stem cells. The findings represent an important advancement in the research centred on one of the most aggressive brain tumours, the glioblastoma multiforme
07 Sep 2010
Princess Margaret Cancer Centre, Vall d’Hebron Institute of Oncology partner to advance personalized cancer medicine
Source: Princess Margaret Cancer Centre TORONTO, Canada – Feb. 27, 2015 – Two internationally acclaimed cancer centres today announced a…
28 Feb 2015
Genomic alterations decoded for the first time in one of the most serious hereditary cancers
VHIO scientists discover a common factor among different tumours in a patient with Li-Fraumeni syndrome further to whole-genome sequencing This…
07 Oct 2013
Novel Akt inhibitor ipatasertib evidenced as a promising contender for therapy against solid tumors
Powerful downmodulation of Akt signaling with ipatasertib proves effective and tolerable in subgroup of patients who have developed resistance to…
01 Dec 2016
Proteins secreted via alternative pathways: potential candidate cancer biomarkers
VHIO Communications talks to Josep Villanueva, PI of VHIO´s Tumour Biomarkers Group, about the latest developments in tumour biomarkers and…
04 Jul 2013
The promise of an active surveillance strategy in patients with metastatic renal cancer
VHIO co-collaborates in a prospective, phase II clinical trial studying patients with metastatic renal-cell carcinoma Findings evidenced active surveillance as…
13 Sep 2016
VHIO collaborates in study identifying a novel therapeutic target for triple-negative breast cancer
• The PIM1 proto-oncogene evidenced as new therapeutic target through which to sensitize triple-negative breast tumours to chemotherapy• PIM1…
05 Nov 2016
Extending Lives: Eribulin and EMBRACE Study
Hosted by VHIO, ecancermedicalscience Editor, Gordon McVie interviews lead authors of a recent study published in The Lancet
30 May 2011
EurOPDX: PDX and optimal preclinical study design in partnership
A vital tool in current armory against cancer is the development of patient-derived tumor xenograft (PDX) mouse models that faithfully…
07 Apr 2015
SPECTAcolor viable next generation multinational cancer clinical trial infrastructure: latest results presented during Gastrointestinal Cancers Symposium 2015
SPECTAcolor – Screening Platform for Efficient Clinical Trials Access in Colorectal cancer, funded by a corporate social responsibility program of…
20 Jan 2015
ICREA celebrates 15 years fortifying Catalonia-based research of excellence
ICREA – the Catalan Institution for Research and Advanced Studies, founded back in 2001 with the support of the Catalan…
29 Jun 2016
VHIO´s Javier Cortés joins The Lancet Oncology´s International Advisory Board 2014
Javier Cortés, Principal Investigator of VHIO´s Breast Cancer and Melanoma Group, Specialist Physician at the Oncology Department of the Vall…
28 Oct 2013
VHIO Meet the Editors with AACR´s Cancer Discovery – the new "kid on the block"
Taking place on Monday 24 February 2014, 09:15 – 10:30, we are delighted to advance that Executive Editor of Cancer…
14 Nov 2013
